Successful treatment of co-existent SAPHO syndrome and hidradenitis suppurativa with adalimumab and methotrexate

J Eur Acad Dermatol Venereol. 2019 Oct;33 Suppl 6:40-41. doi: 10.1111/jdv.15849.

Abstract

SAPHO syndrome, namely Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis, is a rare autoinflammatory chronic disease presenting with non-infectious inflammatory osteitis, sterile joint inflammation and skin manifestations, including palmoplantar pustulosis and severe acne. The case of a 15-year-old boy affected by SAPHO syndrome and hidradenitis suppurativa (HS) is presented and discussed. Coexistence of these two diseases may represent a therapeutic challenge and this case confirms literature data reporting the efficacy of the combination of methotrexate and adalimumab in SAPHO complicated by HS.

Publication types

  • Case Reports

MeSH terms

  • Acquired Hyperostosis Syndrome / complications
  • Acquired Hyperostosis Syndrome / drug therapy*
  • Adalimumab / therapeutic use*
  • Adolescent
  • Anti-Inflammatory Agents / therapeutic use*
  • Dermatologic Agents / therapeutic use*
  • Hidradenitis Suppurativa / complications
  • Hidradenitis Suppurativa / drug therapy*
  • Humans
  • Male
  • Methotrexate / therapeutic use*
  • Prednisone / therapeutic use

Substances

  • Anti-Inflammatory Agents
  • Dermatologic Agents
  • Adalimumab
  • Prednisone
  • Methotrexate